REFERENCES
1. Tu YK, Tseng CD, Hsiao CK, et al. Evidence for improved control of hypertension in Taiwan: 1993-2002. J Hypertens. 2008;26:600-6.
2. Chen YJ, Chen IC, Chen YM, et al. Prevalence of genetically defined familial hypercholesterolemia and the impact on acute myocardial infarction in Taiwanese population: a hospital-based study. Front Cardiovasc Med. 2022;9:994662.
3. Nordestgaard BG, Chapman MJ, Humphries SE, et al.; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478-90a.
4. Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014;63:1935-47.
5. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
6. Brautbar A, Ballantyne CM. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol. 2011;8:253-65.
7. Ito MK, McGowan MP, Moriarty PM. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:S38-45.
8. Koivisto UM, Hämäläinen L, Taskinen MR, Kettunen K, Kontula K. Prevalence of familial hypercholesterolemia among young north Karelian patients with coronary heart disease: a study based on diagnosis by polymerase chain reaction. J Lipid Res. 1993;34:269-77. Available from: https://www.sciencedirect.com/science/article/pii/S0022227520407540?via%3Dihub [Last accessed on 27 May 2026].
9. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:S1-8.
10. Hinchcliffe M, Le H, Fimmel A, et al. Diagnostic validation of a familial hypercholesterolaemia cohort provides a model for using targeted next generation DNA sequencing in the clinical setting. Pathology. 2014;46:60-8.
11. Hsiung YC, Lin PC, Chen CS, et al. Identification of a novel LDLR disease-causing variant using capture-based next-generation sequencing screening of familial hypercholesterolemia patients in Taiwan. Atherosclerosis. 2018;277:440-7.
12. Chiou KR, Charng MJ, Chang HM. Array-based resequencing for mutations causing familial hypercholesterolemia. Atherosclerosis. 2011;216:383-9.
13. Cutler DJ, Zwick ME, Carrasquillo MM, et al. High-throughput variation detection and genotyping using microarrays. Genome Res. 2001;11:1913-25.
14. Yang KC, Su YN, Shew JY, et al. LDLR and ApoB are major genetic causes of autosomal dominant hypercholesterolemia in a Taiwanese population. J Formos Med Assoc. 2007;106:799-807.
15. Ademi Z, Watts GF, Pang J, et al. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol. 2014;8:390-400.
16. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet. 1969;2:1380-2.
17. Yoshida A, Morisaki H, Nakaji M, et al. Genetic mutation analysis in Japanese patients with non-syndromic congenital heart disease. J Hum Genet. 2016;61:157-62.
18. Sacramento-Pacheco J, Sánchez-Gómez MB, Gómez-Salgado J, Novo-Muñoz MM, Duarte-Clíments G. Prevalence of cardiovascular risk factors in Spain: a systematic review. J Clin Med. 2023;12:6944.
19. Guillén M, Corella D, Portolés O, González JI, Mulet F, Sáiz C. Prevalence of the methylenetetrahydrofolate reductase 677C > T mutation in the Mediterranean Spanish population. Association with cardiovascular risk factors. Eur J Epidemiol. 2001;17:255-61.
20. Kerr M, Pears R, Miedzybrodzka Z, et al. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. Eur Heart J. 2017;38:1832-9.
21. Chora JR, Iacocca MA, Tichý L, et al. The clinical genome resource (ClinGen) familial hypercholesterolemia variant curation expert panel consensus guidelines for LDLR variant classification. Genet Med. 2022;24:293-306.
22. Reeskamp LF, Tromp TR, Defesche JC, et al. Next-generation sequencing to confirm clinical familial hypercholesterolemia. Eur J Prev Cardiol. 2021;28:875-83.
23. Alonso R, Perez de Isla L, Muñiz-Grijalvo O, Diaz-Diaz JL, Mata P. Familial hypercholesterolaemia diagnosis and management. Eur Cardiol. 2018;13:14-20.
24. Ned RM, Sijbrands EJ. Cascade screening for familial hypercholesterolemia (FH). PLoS Curr. 2011;3:RRN1238.
25. Pisciotta L, Fasano T, Bellocchio A, et al. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis. 2007;194:e116-22.
26. Vavlukis M, Vavlukis A. Adding ezetimibe to statin therapy: latest evidence and clinical implications. Drugs Context. 2018;7:212534.
27. Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev. 2018;11:CD012502.
28. Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383:711-20.
29. Chiou KR, Charng MJ. Detection of mutations and large rearrangements of the low-density lipoprotein receptor gene in Taiwanese patients with familial hypercholesterolemia. Am J Cardiol. 2010;105:1752-8.
30. Huang CC, Niu DM, Charng MJ. Genetic analysis in a Taiwanese cohort of 750 index patients with clinically diagnosed familial hypercholesterolemia. J Atheroscler Thromb. 2022;29:639-53.
31. Davignon J, Roy M. Familial hypercholesterolemia in French-Canadians: taking advantage of the presence of a “founder effect”. Am J Cardiol. 1993;72:6D-10D.
32. D'Erasmo L, Minicocci I, Di Costanzo A, et al. Clinical Implications of monogenic versus polygenic hypercholesterolemia: long-term response to treatment, coronary atherosclerosis burden, and cardiovascular events. J Am Heart Assoc. 2021;10:e018932.
